Please try another search
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Name | Age | Since | Title |
---|---|---|---|
Adam J. Rosenberg | 53 | 2020 | Independent Director |
Liam Ratcliffe | 61 | 2019 | Lead Independent Director |
Andrew Levin | 46 | 2018 | Principal Financial Officer & Executive Chairman |
Judith A. Dunn | 61 | 2021 | Independent Director |
Simon Tate | 57 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review